PURPOSE: We evaluated the ability of the ketogenic diet (KD) to improve thresholds to flurothyl-induced seizures in two mouse lines with Scn1a mutations: one that models Dravet syndrome (DS) and another that models genetic (generalized) epilepsy with febrile seizures plus (GEFS+). METHODS: At postnatal day 21, mouse models of DS and GEFS+ were fasted for 12-14 h and then placed on either a 6:1 (fats to proteins and carbohydrates) KD or a standard diet (SD) for 2 weeks. At the end of the 2-week period, we measured thresholds to seizures induced by the chemiconvulsant flurothyl. Body weight, β-hydroxybutyrate (BHB) levels, and glucose levels were also recorded every 2 days over a 2-week period in separate cohorts of mutant and wild-type mice that were either on the KD or the SD. KEY FINDINGS: Mice on the KD gained less weight and exhibited significantly higher BHB levels compared to mice on the SD. It is notable that thresholds to flurothyl-induced seizures were restored to more normal levels in both mouse lines after 2 weeks on the KD. SIGNIFICANCE: These results indicate that the KD may be an effective treatment for refractory patients with SCN1A mutations. The availability of mouse models of DS and GEFS+ also provides an opportunity to better understand the mechanism of action of the KD, which may facilitate the development of improved treatments. Wiley Periodicals, Inc.
PURPOSE: We evaluated the ability of the ketogenic diet (KD) to improve thresholds to flurothyl-induced seizures in two mouse lines with Scn1a mutations: one that models Dravet syndrome (DS) and another that models genetic (generalized) epilepsy with febrile seizures plus (GEFS+). METHODS: At postnatal day 21, mouse models of DS and GEFS+ were fasted for 12-14 h and then placed on either a 6:1 (fats to proteins and carbohydrates) KD or a standard diet (SD) for 2 weeks. At the end of the 2-week period, we measured thresholds to seizures induced by the chemiconvulsant flurothyl. Body weight, β-hydroxybutyrate (BHB) levels, and glucose levels were also recorded every 2 days over a 2-week period in separate cohorts of mutant and wild-type mice that were either on the KD or the SD. KEY FINDINGS:Mice on the KD gained less weight and exhibited significantly higher BHB levels compared to mice on the SD. It is notable that thresholds to flurothyl-induced seizures were restored to more normal levels in both mouse lines after 2 weeks on the KD. SIGNIFICANCE: These results indicate that the KD may be an effective treatment for refractory patients with SCN1A mutations. The availability of mouse models of DS and GEFS+ also provides an opportunity to better understand the mechanism of action of the KD, which may facilitate the development of improved treatments. Wiley Periodicals, Inc.
Authors: Frank H Yu; Massimo Mantegazza; Ruth E Westenbroek; Carol A Robbins; Franck Kalume; Kimberly A Burton; William J Spain; G Stanley McKnight; Todd Scheuer; William A Catterall Journal: Nat Neurosci Date: 2006-08-20 Impact factor: 24.884
Authors: Melinda S Martin; Bin Tang; Ligia A Papale; Frank H Yu; William A Catterall; Andrew Escayg Journal: Hum Mol Genet Date: 2007-09-19 Impact factor: 6.150
Authors: Lieve R F Claes; Liesbet Deprez; Arvid Suls; Jonathan Baets; Katrien Smets; Tine Van Dyck; Tine Deconinck; Albena Jordanova; Peter De Jonghe Journal: Hum Mutat Date: 2009-10 Impact factor: 4.878
Authors: Arthur J Barela; Salina P Waddy; Jay G Lickfett; Jessica Hunter; Aimee Anido; Sandra L Helmers; Alan L Goldin; Andrew Escayg Journal: J Neurosci Date: 2006-03-08 Impact factor: 6.167
Authors: Stacey B B Dutton; Karoni Dutt; Ligia A Papale; Sandra Helmers; Alan L Goldin; Andrew Escayg Journal: Exp Neurol Date: 2017-04-01 Impact factor: 5.330
Authors: Brian J Dlouhy; Brandon Miller; Anna Jeong; Mary E Bertrand; David D Limbrick; Matthew D Smyth Journal: Childs Nerv Syst Date: 2016-07-27 Impact factor: 1.475
Authors: Christine A Olson; Helen E Vuong; Jessica M Yano; Qingxing Y Liang; David J Nusbaum; Elaine Y Hsiao Journal: Cell Date: 2018-05-24 Impact factor: 41.582